论文部分内容阅读
目的探讨米非司酮治疗子宫肌瘤的临床疗效。方法分析我院2010年1月至2011年12月105例采用米非司酮治疗的子宫肌瘤患者的临床资料,比较患者治疗前后的各项指标,对米非司酮的疗效及安全性进行综合评估。结果105例患者用药治疗期间有96例闭经(91.43%),102例月经复潮患者停药3个月时行经时间和月经量与治疗前相比有所改善,差异有统计学意义(P<0.01)。停药3个月时,105例患者子宫肌瘤体积平均缩小45.51%,血红蛋白水平提高,雌、孕激素水平较治疗前降低(P均<0.01)。所有患者无严重不良反应发生。结论米非司酮治疗子宫肌瘤短期疗效确定,不良反应小,丰富了保守治疗方法,值得临床推广应用。
Objective To investigate the clinical efficacy of mifepristone in the treatment of uterine fibroids. Methods The clinical data of 105 patients with uterine fibroids treated with mifepristone from January 2010 to December 2011 in our hospital were analyzed. The indexes before and after treatment were compared and the efficacy and safety of mifepristone Comprehensive Evaluation. Results A total of 96 cases of amenorrhea (91.43%) were treated in 105 patients during the treatment period. The time and menstrual flow of 102 patients with menstruation and recuperation after stopping the drug for 3 months were improved compared with that before treatment, the difference was statistically significant (P < 0.01). At 3 months after discontinuation, the volume of uterine fibroids was reduced by 45.51% on average in 105 cases, hemoglobin level was increased, and estrogen and progesterone levels were lower than those before treatment (all P <0.01). No serious adverse reactions occurred in all patients. Conclusion Mifepristone treatment of uterine fibroids short-term curative effect is determined, the adverse reaction is small, enriched the conservative treatment, it is worth clinical promotion and application.